Armando Filie, M.D.

Senior Clinician

Laboratory of Pathology

NCI/CCR

Building 10 - Magnuson CC, Room 2A19
Bethesda, MD 20892

301-480-8055

afilie@mail.nih.gov

Research Topics

The goals of the Cytopathology Section are to provide accurate, timely, sophisticated diagnoses to guide patient treatment and to support clinical protocols and research at NIH. This is accomplished through the diagnostic service as well as the application of established and newly developed ancillary/research techniques to clinical and research samples.

Cytopathology provides diagnostic evaluation of cytology specimens that direct patient management and treatment. The Section provides complete diagnostic services for various clinical protocols at the NIH Clinical Center. We specialize in the application of ancillary techniques (i.e., immunoperoxidase, flow cytometry and, most recently, molecular testing) to patient material for the confirmation of morphologic diagnoses, evaluation for protocol entry criteria and collaborative investigations. 

Due to the nature of the specimen material evaluated by our Section, often our cases require immunoperoxidase studies (12 percent). The immunosuppressed nature of our patient population at the NIH dictates that a significant proportion of our cases require special studies for pathologic organisms (12 percent). The relatively high rate of pathologic findings, combined with the diversity of types of exfoliative and fine needle aspiration (FNA) specimens, provides a broad experience in diagnostic cytopathology for residency and fellowship training.

The Section is involved in numerous clinical research studies, many of which use FNA or exfoliative samples with immunocytochemistry and/or molecular techniques to provide ancillary diagnostic information. Examples of such studies include:

  • Evaluation of expression of malignant melanoma markers (MART-1 and gp100) through the utilization of antibodies in ex-vivo FNAs from malignant melanoma patients; 
  • Evaluation of expression of epithelial markers (CK AE1/AE3 and CK 8/18) through the utilization of antibodies in ex-vivo FNAs from gastrointestinal carcinoma patients; 
  • Evaluation of expression of epithelial markers (CK AE1/AE3 and CK 8/18) through the utilization of antibodies in ex-vivo FNAs from non-gastrointestinal carcinoma patients;
  • Morphologic and immunocytochemical evaluation of tumor infiltrating lymphocytes samples for possible tumor cell contamination prior to therapy;
  • FNA material for subsequent analysis by polymerase chain reaction (PCR), microarray, and other molecular technologies;
  • Evaluation of cell lines by morphology and immunocytochemistry; and 
  • Application of RNA-based molecular technique to non-gynecologic and FNA cytology samples to enhance diagnosis, prognosis and patient management.

Biography

Dr. Filie is a graduate of the Santos School of Medical Sciences, Brazil. He completed residency training in Anatomic Pathology at Georgetown University Medical Center and fellowship training in Cytopathology at George Washington University Medical Center. After his fellowship, Dr. Filie joined the NCI in 1996 and serve as the director of the ACGME-accredited cytopathology fellowship training program at the Laboratory of Pathology, NCI. Dr. Filie's clinical research interests are related to the application of new ancillary techniques to cytopathology, immunocytochemistry, fine needle aspiration and thyroid.

Selected Publications

  1. Rosenberg AZ, Armani MD, Fetsch PA, Xi L, Pham TT, Raffeld M, Chen Y, O'Flaherty N, Stussman R, Blackler AR, Du Q, Hanson JC, Roth MJ, Filie AC, Roh MH, Emmert-Buck MR, Hipp JD, Tangrea MA. High-Throughput Microdissection for Next-Generation Sequencing. PLoS One. 2016;11(3):e0151775.

  2. Layfield LJ, Ehya H, Filie AC, Hruban RH, Jhala N, Joseph L, Vielh P, Pitman MB, Papanicolaou Society of Cytopathology.. Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytology. Diagn Cytopathol. 2014;42(4):351-62.

  3. Chowdhuri SR, Xi L, Pham TH, Hanson J, Rodriguez-Canales J, Berman A, Rajan A, Giaccone G, Emmert-Buck M, Raffeld M, Filie AC. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol. 2012;25(4):548-55.

  4. Roy Chowdhuri S, Hanson J, Cheng J, Rodriguez-Canales J, Fetsch P, Balis U, Filie AC, Giaccone G, Emmert-Buck MR, Hipp JD. Semiautomated laser capture microdissection of lung adenocarcinoma cytology samples. Acta Cytol. 2012;56(6):622-31.

  5. Filie AC, Asa SL, Geisinger KR, Logani S, Merino M, Nikiforov YE, Clark DP. Utilization of ancillary studies in thyroid fine needle aspirates: a synopsis of the National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008;36(6):438-41.


This page was last updated on September 13th, 2019